SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

SEGALA, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.091
EU - Europa 2.912
AS - Asia 1.615
SA - Sud America 116
AF - Africa 20
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 9.767
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.056
IT - Italia 1.288
SG - Singapore 775
PL - Polonia 717
CN - Cina 502
DE - Germania 281
GB - Regno Unito 137
ID - Indonesia 117
FI - Finlandia 111
BR - Brasile 102
UA - Ucraina 95
SE - Svezia 87
VN - Vietnam 70
TR - Turchia 69
FR - Francia 45
AT - Austria 31
NL - Olanda 29
CA - Canada 26
BE - Belgio 25
LT - Lituania 18
IN - India 17
HK - Hong Kong 12
CM - Camerun 9
IE - Irlanda 8
KR - Corea 8
RU - Federazione Russa 8
CZ - Repubblica Ceca 7
AU - Australia 6
BD - Bangladesh 6
CH - Svizzera 6
EU - Europa 5
IQ - Iraq 4
PE - Perù 4
AR - Argentina 3
BG - Bulgaria 3
DO - Repubblica Dominicana 3
GE - Georgia 3
IR - Iran 3
KZ - Kazakistan 3
MA - Marocco 3
MY - Malesia 3
NO - Norvegia 3
RS - Serbia 3
TH - Thailandia 3
TN - Tunisia 3
ZA - Sudafrica 3
AL - Albania 2
CL - Cile 2
CO - Colombia 2
DK - Danimarca 2
EC - Ecuador 2
IL - Israele 2
JP - Giappone 2
LK - Sri Lanka 2
MX - Messico 2
PH - Filippine 2
PK - Pakistan 2
AE - Emirati Arabi Uniti 1
AP - ???statistics.table.value.countryCode.AP??? 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
EG - Egitto 1
ES - Italia 1
HU - Ungheria 1
IM - Isola di Man 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
SA - Arabia Saudita 1
SM - San Marino 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 9.767
Salva come PNG Salva come JPEG
Città #
Warsaw 715
Fairfield 588
Santa Clara 552
Ashburn 548
Singapore 492
Chandler 348
Woodbridge 309
Beijing 248
Houston 237
Wilmington 236
Seattle 218
Cambridge 176
Princeton 154
Ferrara 128
Jakarta 113
Ann Arbor 111
Jacksonville 102
Munich 97
Milan 91
Helsinki 85
Dong Ket 69
San Diego 68
Shanghai 68
Bremen 59
Rome 52
Los Angeles 48
Izmir 47
Bologna 45
London 43
Washington 42
Boardman 38
Falls Church 37
Nanjing 37
Nuremberg 32
Redwood City 31
Dearborn 27
Addison 26
Brussels 23
Falkenstein 22
Santa Maria Di Sala 22
New York 19
Verona 16
Mountain View 15
Norwalk 15
San Mateo 15
Frankfurt am Main 14
Padova 14
Toronto 12
Hong Kong 11
Portsmouth 11
Vienna 11
Shenyang 10
Tianjin 10
Nanchang 9
Lauterbourg 8
Louisville 8
Ottawa 8
Augusta 7
Ferrara di Monte Baldo 7
Florence 7
Jiaxing 7
Lappeenranta 7
Palermo 7
Belo Horizonte 6
Chicago 6
Hebei 6
Jinan 6
Naples 6
São Paulo 6
Turin 6
Zhengzhou 6
Andover 5
Auburn Hills 5
Castelnuovo Rangone 5
Chiswick 5
Cordenons 5
Dublin 5
Feltre 5
Pisa 5
Taizhou 5
Arezzo 4
Birmingham 4
Forlì 4
Genoa 4
Guangzhou 4
Hangzhou 4
Kunming 4
Messina 4
Paris 4
Parma 4
Rimini 4
Torino 4
Trento 4
Zonguldak 4
Amsterdam 3
Ancona 3
Brasília 3
Brescia 3
Brno 3
Cagliari 3
Totale 6.799
Salva come PNG Salva come JPEG
Nome #
Endocardite da Bartonella henselae? Riscontro di anticorpi anti-fosfolipidi, anti-beta2-glicoproteina e anti-cardiolipina. 579
Daclatasvir + Sofosbuvir +/- Ribavirin in HIV/HCV co-infected patients with advanced liver disease: preliminary data from the Italian Compassionate Use Program 271
INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI 200
Proportion of PLWH not vaccinated for COVID-19 in Italy and predictors 156
INDAGINE RETROSPETTIVA DELLE LINFOADENOPATIE INFETTIVE. RUOLO DEI TESTS MOLECOLARI. 142
INFEZIONI DEL SISTEMA NERVOSO CENTRALE E CHLAMYDIA PNEUMONIAE. RUOLO ETIOPATOGENETICO NELLA SCLEROSI MULTIPLA 126
Expression of toxoplasmic 65 kDa cystic mRNA by RT-PCR in patients with Toxoplasma gondii infection relapses 120
Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area. 118
Investigation of Chlamydia pneumonite and Mycoplasma spp. In clinical specimens from patients with arhritis 115
The role of stage-specific oligonucleotide primers in providing effective laboratory support for the molecular diagnosis of reactivated Toxoplasma gondii encephalitis in patients with AIDS 106
HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients 106
null 106
Recovery of Enterococcus gallinarum in patients with infected cardiac pacemaker pockets. 101
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 101
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 97
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 97
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 95
EPATITE CRONICA C E SINDROME DI EHLERS DANLOS (EDS). 94
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: data from the Icona cohort 94
Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation 88
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients 86
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 86
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection 84
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 84
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy 84
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing 83
Approccio multidisciplinare per il trattamento delle osteomieliti croniche e delle infezioni di dispositivi ortopedici. Risultati Preliminari 81
A prospective randomized trial on abacavir/ lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study) 79
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort * 79
Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study 79
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 78
Implicazioni diagnostiche e terapeutiche in un paziente con Infezione da Parvovirus B-19 e sarcoidosi 77
EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE 77
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 77
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 77
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 77
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 77
Atazanavir/rit(atz/r),unboosted atazanavir (atz) or darunavir/rit(drv/r):metabolic safety and liver fibrosis in hiv/hcv coinfected patients (master cohort) 77
Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV-related condition in the real life practice 76
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 75
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 75
Disease progression in HIV Late Presenters: The role of HIV clinical indicator diseases prior to HIV diagnosis 74
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 74
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 73
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 73
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 73
L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV 73
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 73
Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study 72
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 72
Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: A multicentre cohort study Disease epidemiology - Infectious 72
Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D: A: D study 72
Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals? 72
Therapeutic immunization with hiv-1 tat reduces immune activation and loss of regulatory t-cells and improves immune function in subjects on HAART 72
Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort 71
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 71
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 70
Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the Icona Foundation Cohort 70
Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D study 69
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 68
The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study 68
RISPOSTA VIROLOGICA SOSTENUTA DOPO TRATTAMENTO BREVE CON DI PEGINTERFERON ALFA-2A E RIBAVIRINA IN CORSO DI EPATITE CRONICA DA HCV 67
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 67
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients 66
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 66
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 65
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients 65
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 64
Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen 64
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 63
FOLLOW-UP SIEROLOGICO DI PAZIENTE AFFETTO DA RECIDIVA DI IDATIDOSI EPATICA ED INTOLLERANZA ALL’ALBENDAZOLO (ABZ). 61
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 60
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort 59
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 59
TB meningitis in HIV-positive patients in Europe and Argentina: Clinical dutcome and factors associated with mortality 59
Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens 59
Broncopolmonite con empieva pleurico da Streptococcus pluranimalium in paziente tossicodipendente: considerazioni clinico-epidemiologiche. 59
Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings 59
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 58
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 58
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 58
RIACUTIZZAZIONE DI EPATITE CRONICA HBV-RELATA DOPO VACCINAZIONE ANTINFLUENZALE. DESCRIZIONE DI UN CASO CLINICO 57
Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter? 57
Associations between immune depression and cardiovascular events in HIV infection 56
Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome 55
Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study 53
null 53
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort 52
Factors that influence HCV related liver disease severity in Italian patients in care: data from PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti ViRali) HCV cohort study". 52
Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy 52
Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: The D:A:D Study a 51
Antiretroviral Regimens Containing Atazanavir/Ritonavir (ATZ/R) Unboosted Atazanavir (ATZ) or Darunavir/Ritonavir (DRV/R) in HIV/HCV-coinfected Patients: Evaluation of Safety, Effectivness And Impact on Liver Fibrosis (MASTER Cohort) 51
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice 51
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 50
COVID-19 in eastern Emilia: an unusual epidemiology in Northern Italy 50
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: Relation with patient and cohort characteristics 49
Optimization of hepatitis C virus screening strategies by birth cohort in Italy 49
Time to undetectable viral load achievement after art start and risk of mortality. 49
null 48
Multidrug Resistant Bacterial Co-Infections in Critically Ill Patients with COVID-19: A Review after Three Years of Pandemic 47
Totale 8.230
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.373
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 1.433
Totale 72.806
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.013 0 0 0 0 0 0 0 0 398 294 158 163
2020/20212.578 142 269 132 312 301 303 224 211 124 310 89 161
2021/20221.086 74 96 23 15 57 89 56 65 38 121 53 399
2022/2023988 158 65 66 54 173 92 52 95 117 12 71 33
2023/20241.102 55 100 82 41 115 223 27 74 34 29 37 285
2024/20252.418 101 88 350 163 469 482 155 167 443 0 0 0
Totale 10.139